Table 4.
Telavancin dosing and duration of therapy by patient baseline renal function
| Telavancin exposure characteristics | Dialysis (n = 13) | Baseline CrCl (mL/min)a | Total (N = 151) | |||
|---|---|---|---|---|---|---|
| < 30 (n = 5) | 30 to < 50 (n = 10) | 50 to < 80 (n = 18) | ≥ 80 (n = 77) | |||
| Average daily dose (mg)b | ||||||
| Mean (SD) | 465.9 (235.5) | 601.6 (291.0) | 617.6 (114.9) | 641.0 (161.1) | 748.8 (186.0) | 688.5 (207.6) |
| Median (IQR) | 422.7 (215.1) | 625.0 (409.8) | 650.0 (201.6) | 600.0 (207.7) | 750.0 (80.0) | 740.6 (206.0) |
| Duration of therapy (days) | ||||||
| Mean (SD) | 24.4 (20.5) | 16.8 (18.6) | 17.0 (18.3) | 8.4 (10.6) | 13.4 (13.5) | 17.2 (16.5) |
| Median (IQR) | 17.0 (30.0) | 12.0 (4.0) | 6.0 (28.0) | 5.0 (6.0) | 8.0 (12.0) | 9.0 (24.0) |
| Average daily dose per body weight (mg/kg) | ||||||
| Mean (SD) | 5.3 (2.5) | 7.3 (2.9) | 8.4 (2.3) | 8.9 (1.5) | 9.1 (1.8) | 8.4 (2.3) |
| Median (IQR) | 4.4 (3.2) | 6.0 (4.0) | 8.1 (2.9) | 7.8 (6.5) | 9.3 (2.4) | 8.7 (2.8) |
| Telavancin dose adjustedc | ||||||
| n (%) | 2 (15.4) | 2 (40.0) | 2 (20.0) | 4 (22.2) | 10 (13.0) | 22 (14.6) |
CrCl creatinine clearance, IQR interquartile range, SD standard deviation
aBaseline CrCl was not estimated for 27 patients because the baseline serum creatinine concentration was not recorded, and for 1 patient due to missing age
bAverage daily dose per body weight was calculated to account for different dosing schedules. 139 patients were dosed every 24 h, 8 were dosed every 48 h, and 4 were dosed at a frequency recorded as “other.”
cPatients whose dose changed from the initial recorded dose